Evidence map›Paper›PMID 36149967›Full record

ArticleScience advances2022

Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation.

Jui-Lin Chen, Chelsea N Fries, Stella J Berendam, Nicole S Rodgers, Emily F Roe, Yaoying Wu, Shuk Hang Li, Rishabh Jain, Brian Watts, Joshua Eudailey and 8 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Jui-Lin ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-7646-4907
Chelsea N FriesDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Stella J BerendamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Nicole S RodgersDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Emily F RoeDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-4585-3704
Yaoying WuDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-0570-2493
Shuk Hang LiThe Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-8462-6657
Rishabh JainDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID 0000-0001-9449-8521
Brian WattsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-1731-2441
Joshua EudaileyDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.
Richard BarfieldDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham NC 27710, USA.
Cliburn ChanDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham NC 27710, USA.ORCID 0000-0001-5901-6806
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-3890-5855
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-7399-7954
Justin PollaraDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-1892-4722
Sallie R PermarDepartment of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0003-1438-4554
Joel H CollierDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-3536-4827
Genevieve G FoudaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-0960-1019
Duke University · USCornell University · USUniversity of Pennsylvania · US

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
University Training Program in Biomolecular & Tissue EngineeringT32GM008555 · NIGMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 1994 to 2021
$8.1M
Supramolecular pediatric HIV vaccine designR01AI145016 · NIAID · DUKE UNIVERSITY · PI COLLIER, JOEL H, FOUDA AMOU OU, GENEVIEVE GINY · 2019 to 2022
$3.1M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI145016NIAID NIH HHS T32 AI007392NIGMS NIH HHS T32 GM008555NIGMS NIH HHS T32 GM144291
6 · The paper itself

Abstract

To develop vaccines for certain key global pathogens such as HIV, it is crucial to elicit both neutralizing and non-neutralizing Fc-mediated effector antibody functions. Clinical evidence indicates that non-neutralizing antibody functions including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) contribute to protection against several pathogens. In this study, we demonstrated that conjugation of HIV Envelope (Env) antigen gp120 to a self-assembling nanofiber material named Q11 induced antibodies with higher breadth and functionality when compared to soluble gp120. Immunization with Q11-conjugated gp120 vaccine (gp120-Q11) demonstrated higher tier 1 neutralization, ADCP, and ADCC as compared to soluble gp120. Moreover, Q11 conjugation altered the Fc N-glycosylation profile of antigen-specific antibodies, leading to a phenotype associated with increased ADCC in animals immunized with gp120-Q11. Thus, this nanomaterial vaccine strategy can enhance non-neutralizing antibody functions possibly through modulation of immunoglobulin G Fc N-glycosylation.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsNanofibersAnimalsGlycosylationHIV AntibodiesImmunoglobulin Fc FragmentsImmunoglobulin GVaccines, SubunitAIDS VaccinesHIV AntibodiesImmunoglobulin Fc FragmentsImmunoglobulin GVaccines, Subunit

Identifiers

PMID36149967
PMCPMC9506727
OpenAlexW4297016531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.